We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in IQVIA Holdings (IQV) Now
Read MoreHide Full Article
IQVIA Holdings Inc.’s (IQV - Free Report) enormous treasure trove of information is a distinguishing asset and perhaps a big barrier to entry for competitors. The company has a huge collection of healthcare information that encompasses more than 1.2 billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media.
IQVIA’s addressable market, with a size of more than $210 billion, consists of outsourced research and development, real-world evidence and connected health, and technology-enabled clinical and commercial operation markets. The company aims to expand into these markets by innovating and improving its offerings using its information, advanced analytics, transformative technology and significant domain expertise.
Let’s take a look at some other factors that make the stock an attractive pick.
Solid Rank: IQV currently carries a Zacks Rank #2 (Buy) and has a VGM Score of B. Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, offer the best investment opportunities for investors. Thus, the company appears to be a compelling investment proposition at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Northward Estimate Revisions: Two estimates for 2022 moved north in the past 60 days versus no southward revision, reflecting analysts’ confidence in the company. The Zacks Consensus Estimate for 2022 earnings has moved up 1.5% in the past 60 days.
Positive Earnings Surprise History: IQV has an impressive earnings surprise history. The company outpaced the Zacks Consensus Estimate in all of the trailing four quarters, delivering an earnings surprise of 2.6%, on average.
Strong Growth Prospects: The Zacks Consensus Estimate for IQV’s 2022 earnings is pegged at $10.12, reflecting 12.1% year-over-year growth. Moreover, earnings are expected to register a 13.1% increase in 2023.
Other Stocks to Consider
Investors interested in the broader Zacks Business Services sector can also consider stocks like Paychex, Inc. (PAYX - Free Report) and Cross Country Healthcare, Inc. (CCRN - Free Report) .
Paychex carries a Zacks Rank #2 at present. PAYX has a long-term earnings growth expectation of 7.5%.
Paychex delivered a trailing four-quarter earnings surprise of 8.6%, on average.
Cross Country Healthcare currently carries a Zacks Rank of 2. CCRN has a long-term earnings growth expectation of 10%.
CCRN delivered a trailing four-quarter earnings surprise of 26%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Invest in IQVIA Holdings (IQV) Now
IQVIA Holdings Inc.’s (IQV - Free Report) enormous treasure trove of information is a distinguishing asset and perhaps a big barrier to entry for competitors. The company has a huge collection of healthcare information that encompasses more than 1.2 billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media.
IQVIA’s addressable market, with a size of more than $210 billion, consists of outsourced research and development, real-world evidence and connected health, and technology-enabled clinical and commercial operation markets. The company aims to expand into these markets by innovating and improving its offerings using its information, advanced analytics, transformative technology and significant domain expertise.
Let’s take a look at some other factors that make the stock an attractive pick.
Solid Rank: IQV currently carries a Zacks Rank #2 (Buy) and has a VGM Score of B. Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, offer the best investment opportunities for investors. Thus, the company appears to be a compelling investment proposition at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Northward Estimate Revisions: Two estimates for 2022 moved north in the past 60 days versus no southward revision, reflecting analysts’ confidence in the company. The Zacks Consensus Estimate for 2022 earnings has moved up 1.5% in the past 60 days.
Positive Earnings Surprise History: IQV has an impressive earnings surprise history. The company outpaced the Zacks Consensus Estimate in all of the trailing four quarters, delivering an earnings surprise of 2.6%, on average.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
Strong Growth Prospects: The Zacks Consensus Estimate for IQV’s 2022 earnings is pegged at $10.12, reflecting 12.1% year-over-year growth. Moreover, earnings are expected to register a 13.1% increase in 2023.
Other Stocks to Consider
Investors interested in the broader Zacks Business Services sector can also consider stocks like Paychex, Inc. (PAYX - Free Report) and Cross Country Healthcare, Inc. (CCRN - Free Report) .
Paychex carries a Zacks Rank #2 at present. PAYX has a long-term earnings growth expectation of 7.5%.
Paychex delivered a trailing four-quarter earnings surprise of 8.6%, on average.
Cross Country Healthcare currently carries a Zacks Rank of 2. CCRN has a long-term earnings growth expectation of 10%.
CCRN delivered a trailing four-quarter earnings surprise of 26%, on average.